Background: The prognostic effect of pretreatment elevated platelet count remains controversial in colorectal cancer patients. We conducted this meta-analysis to evaluate the prognostic impact of it in these patients.
INTRODUCTION
Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million cases and 693,900 deaths occurring in 2012 [1] . Several markers like carcinoembryonic antigen, C-reactive protein, albumin and tumor necrosis factors have been reported as prognostic indicators of outcomes in patients with colorectal cancer. However, it is still difficult to predict the outcome of patients before treatment.
There is a growing body of evidence showing that elevated platelet count or thrombocytosis is associated with outcomes of colorectal cancer [2] [3] [4] [5] [6] [7] [8] [9] [10] . Early in 1998, Monreal M et al. reported a significant association between pre-operative platelet count and survival in patients with colorectal cancer. The following studies confirmed this association [2, 3, 5, 6] . However, some other studies failed to demonstrate the association between pretreatment elevated platelet count and outcomes of colorectal cancer [11] [12] [13] [14] [15] [16] . Considering the controversial evidence, we conduct a meta-analysis to evaluate whether pretreatment elevated platelet count is a prognostic marker of colorectal cancer.
RESULTS

Study selection
Electronic search identified 2604 potentially relevant references. Additional 5 references were further identified by checking the reference list. 2469 duplicates
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or clearly irrelevant references were excluded through reading the abstracts. 140 references were read in full and 106 references were excluded for irrelevance or lack of data on comparisons or outcomes. Four references were excluded for repeated data. Finally, 30 references fulfilled the inclusion criteria and provided data for the metaanalysis (Figure 1 ).
Characteristics of included studies
All thirty included articles were cohort studies published from 1998 to 2016. This meta-analysis included 9123 patients. The quality score of included studies ranged from 6 to 8 stars. Hazard ratios of overall survival were available in 28 included studies and hazard ratios of disease-free survival were available in 15 included studies. Characteristics of the included studies are listed in Table 1 .
Prognostic impact of pretreatment elevated platelet count on overall survival
Twenty-eight studies contributed data to the analyses of overall survival [2-7, 9, 11-31] . Significant heterogeneity was found among studies (I 2 = 81%, p = 0.000, Figure 2 ). Random-effect model was used. The pooled hazard ratio estimate showed that patients with pretreatment elevated platelet count had poorer overall survival compared with normal platelet count (HR = 1.837, 95% confidence interval, 1.497 to 2.255, p = 0.000, Figure 2 ).
We performed subgroup analyses on confounding factors such as disease stage, cancer type, cut-off values, etc. The results consistently showed that patients with pretreatment elevated platelet count had poorer overall survival compared with normal platelet count in most subgroups: multivariate analysis subgroup (p = 0.000), univariate analysis subgroup (p = 0.000), preoperative subgroup (p = 0.000), metastatic disease subgroup (p = 0.027), stage I-III disease subgroup (p = 0.000), rectal cancer subgroup (p = 0.009), cut-off value ≥ 400 subgroup (p = 0.000), 300 ≤ cut-off value < 400 subgroup (p = 0.000), cut-off value < 300 subgroup (p = 0.043). In colon cancer subgroup, overall survival of patients with pretreatment elevated platelet count had no difference with patients with normal platelet count (p = 0.099). The detailed results of subgroup analyses were summarized in Table 2 .
Prognostic impact of pretreatment elevated platelet count on disease-free survival
Fifteen studies contributed data to the analyses of disease-free survival. Significant heterogeneity was found among studies (I 2 = 82%, p = 0.000, Figure 3 ). Randomeffect model was used. The pooled hazard ratio estimate showed that patients with pretreatment elevated platelet count had poorer disease-free survival compared with normal platelet count (HR = 1.635, 95% confidence interval, 1.237 to 2.160, p = 0.001, Figure 3) .
The results of subgroup analyses revealed that colorectal patients with pretreatment elevated platelet count had poorer disease-free survival compared with normal platelet count in the following subgroups: multivariate analysis subgroup (p = 0.007), preoperative subgroup (p = 0.000), stage I-III disease subgroup (p = 0.007), rectal cancer subgroup (p = 0.003), colon cancer subgroup (p = 0.001), 300 ≤ cut-off value < 400 subgroup (p = 0.000), cut-off value < 300 subgroup (p = 0.003). In three subgroups, patients with pretreatment elevated platelet count had similar disease-free survival compared with patients with normal platelet count: univariate analysis subgroup (p = 0.056), cut-off value ≥ 400 subgroup (p = 0.056) and metastatic disease subgroup (all patients received R0 resection of primary and metastasis tumors) (p = 1.320). The detailed results of subgroup analyses were summarized in Table 2 .
Publication bias
Visual inspection of the funnel plot for overall survival and disease-free survival outcomes did not show the typically asymmetry associated with publication bias (Figure 4, Figure 5 ). Evidence of publication bias was also not seen with the Begg's tests of overall survival (p = 0.441) and disease-free survival (p = 1.000).
Sensitivity analyses
The result of Sensitivity analyses demonstrated that no individual study had excessive influence on the stability of the pooled effect of comparisons for overall survival ( Figure 6 ) and disease-free survival (Figure 7 ). The result of this meta-analysis is robust.
DISCUSSION
Elevated platelet count or thrombocytosis is observed in patients with various kinds of cancer and reported inversely correlated with survival [24, [32] [33] [34] [35] [36] . It was reported that nearly 10% to 30% of patients with colorectal cancer had elevated platelet count before treatment and worse survival than those with normal platelet count [2-5, 7, 9, 21] . In our study, the results demonstrated that elevated platelet count was associated with shorter overall survival and disease-free survival in patients with colorectal cancer. Subgroup analyses demonstrated that the impact of elevated platelet count are consistent in different disease stages, tumor locations and analysis models. The result of our study is robust. This evidence indicated that platelet could be a simple and robust prognostic marker to identify high risk patients. Those patients should be taken into account to receive adjuvant therapy or maybe anti-platelet medications. There have been accumulating evidence that postdiagnosis aspirin therapy can improve overall survival of patients with colorectal cancer in recent years [37] . It is noteworthy that the cut-off values applied in included studies were not unified. Most studies used 400 × 10 9 /L as cut-off value and some studies used 300 × 10 9 /L. The optimal cut-off value, however, was not validated in previous studies. The subgroup analyses reached consistent results among different cut-off value subgroup.
The cut-off value ≥ 400 × 10 9 / L and between 300 and 400 can both distinguished patients well by overall survival and disease-free survival. Only in cut-off value ≥ 400 × 10 9 / L subgroup, platelet count failed to predict the disease-free survival of patients (p = 0.056, Table 2 ). Regarding this, it may be reasonable to suggest that the cut-off value between 300 and 400 × 10 9 / L be applied in further investigation.
The mechanisms of tumor-related elevated platelet count or thrombocytosis remain undetermined. One of the potential hypotheses is that thrombocytosis is usually associated with inflammatory cytokines induced by interactions between tumor and host. Among these cytokines, IL-6, having multiple functions in many physiological conditions, plays a very important role in the formation of thrombocytosis [38] . By stimulating differentiation of megakaryocytes to platelets in the bone marrow, IL-6 induced thrombocytosis in various malignancies [39] . For another explanation of cancerassociated thrombocytosis, tumor can stimulate activation of platelet. As reported in several studies that cancer cells can secrete vascular endothelial growth factor to stimulates megakaryocyte differentiation [40] . For the prognostic association between elevated platelet count and patients' outcomes, there is a most widely accepted hypothesis that activated platelets contribute to the tumor growth, angiogenesis and metastasis by releasing various cytokines with inflammatory, proliferative and angiogenic activity [41] [42] [43] . With regard to tumor metastasis, platelets can cover and protect circulating tumor cells from the host's immune system. With these underlying mechanisms, platelets may be a direct or indirect target for cancer therapy. There are some limitations of this study. First, our analysis is based on low-level evidence retrospective studies, in most of which some important confounders were not well adjusted, such as tumor stage, therapeutic strategy or ratio of colon and rectal cancer. The result of subgroup analysis, however, demonstrated that the negative prognostic significance of thrombocytosis on overall survival and disease-free survival was consistent between groups. Subgroup analysis according to therapeutic strategies was not performed because of insufficient data. Second, the sample size of some included studies were very small. The results of subgroup analyses still confirm the prognostic significance of thrombocytosis. Third, although the platelet count is easy to measure, its utility as a clinical prognostic marker could be affected by some other conditions, such as thrombosis, coronary disease, splenic disease, myeloproliferative disease, blood coagulation disorders, iron deficiency anemia and drugs. Actually, some heterogeneity was unexplainable.
In conclusion, our study demonstrated that the pretreatment elevated platelet count was an independent prognostic factor of overall survival and disease-free survival in colorectal cancer patients. It may make sense www.impactjournals.com/oncotarget that patients with elevated platelet count should receive intensive treatment or anti-platelet therapy. And large-scale prospective studies and a validation study are warranted to confirm its prognostic significance and determine the optimal platelet cut-off value.
MATERIALS AND METHODS
Eligibility criteria
This meta-analysis was performed according to the statement of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [44] . Cohort studies, being published from inception to July 9, 2016, which reported comparisons of overall survival or diseasefree survival between colorectal cancer patients with pretreatment elevated platelet count and those patients with pretreatment normal platelet count. The study participants had been pathologically diagnosed colorectal cancer patients.
Search strategy
An electronic search in PubMed, EMBASE and the Cochrane Library were conducted from inception to July 9, 2016. The following key words in combination as medical subject heading terms and text words were used: "colorectal cancer" and "platelet" or "thrombocytosis". Potentially relevant articles were identified by reading titles and abstracts. The full texts of the relevant articles were read to determine whether they met the inclusion criteria. The references were also searched to identify relevant studies.
Quality assessment
For cohort studies, the 9-star Newcastle-Ottawa Scale was used to assess the risk of bias [45] . This scale is an 8-item instrument that allows for assessment of patient population and selection, study comparability, follow-up, and outcome. Interpretation of the scale is performed by awarding points for high-quality elements. Studies with 5 or more stars were defined as high-quality studies and were included.
Statistical analyses
Data was extracted using a unified form and study information including author name, study year, study area, sample size, hazard ratio of overall survival or diseasefree survival were collected. If the hazard ratio was not reported in the original article, we would calculate hazard ratio from reported data according to the methods described by Tierney et al [46] . Statistical heterogeneity among studies was examined using the Cochrane Q test by calculating the I 2 value [47] . The I 2 value greater than 50% or p value less than 0.05 were considered to represent significant heterogeneity. The pooled hazard ratio and the 95% confidence interval were calculated using the Z test. The pooled hazard ratio and the 95% confidence interval were calculated using the Mantel-Haenszel formula (fixedeffect model) when heterogeneity was not detected (p > 0.05), or using the DerSimonian-Laird formula (randomeffect model) when heterogeneity was significant (p < 0.05) [48] . Publication bias was evaluated using the funnel plot and the Begg's test [49] . Influence analyses were conducted to access how robust the pooled estimators were by removing individual studies. An individual study 
